Overview & Pipeline
Raptor is building a balanced, robust pipeline of drug candidates which may expand the reach and benefit of existing therapeutics. Raptor’s commercial, clinical, and preclinical pipeline includes both candidates from Raptor's proprietary molecules and in-licensed and acquired product candidates.
Raptor's lead product, PROCYSBI™ (cysteamine bitartrate) delayed-release capsules, received FDA approval on April 30, 2013. The Company anticipates receiving a determination from the EMA regarding its PROCYSBI™ marketing application in the European Union in the second half of 2013.
Raptor's clinical-stage product pipeline includes two active development programs based on the Company's proprietary delayed-release formulation of cysteamine bitartrate (RP103 capsules), as well as the Company's Convivia™ (oral 4-methylpyrazole) program which the Company licensed to Uni Pharma Ltd., Taiwan. Raptor's preclinical pipeline includes two development programs based upon the Company's proprietary molecules.
Product Pipeline (Potential Clinical Indications)
Scroll your mouse over the chart to link to relevant Raptor product details.
Clinical Development Pipeline
Raptor has two active clinical development programs based on its proprietary extended and delayed-release formulation of cysteamine bitartrate.
- RP103 capsules for the potential treatment of:
- Huntington's disease, an inherited neurodegenerative disease (Phase 2/3)
- Nonalcoholic Fatty Liver Disease (NAFLD) in Children, a metabolic disorder of the liver (Phase 2b)
Raptor's other clinical development program:
- Convivia™(oral 4-methylpyrazole) for the potential management of acetaldehyde toxicity due to ALDH2 deficiency, an inherited metabolic disorder (Phase 2, licensed to Uni Pharma Ltd., Taiwan)
Convivia™ is a Phase 2 product candidate that addresses ALDH2 deficiency. The ALDH2 enzyme is a component of the primary metabolic pathway for ethanol and other alcohols. Consumption of alcohol by individuals with ALDH2 deficiency leads to an accumulation of acetaldehyde, a known carcinogen, in blood, saliva, liver and other tissues. This condition is commonly known as alcohol intolerance or Asian Flush.
Raptor's preclinical programs consist of: